QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio.

Several leading In Vitro Diagnostic (IVD) companies have posted their first-quarter results for 2026, showing mixed performance across revenue, profitability, and cash flow.

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31, 2026.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026.

Group sales were +6% at constant exchange rates (CER), -5% when reported in CHF and +9% in USD, in the first three months, driven by high demand for our innovative medicines and diagnostics.

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.

Danaher Corporation (NYSE: DHR) today announced results for the first quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.

QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, today announced preliminary unaudited revenue for the first quarter of 2026, ended March 29, 2026, and provided an update on its full-year 2026 financial guidance. The Company also announced its plan to release its full first quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes.

Our cancer diagnostics business, medical devices portfolio and pipeline progress are among key growth drivers.

Abbott (ABT.N), opens new tab cut its annual profit forecast on Thursday due to an impact from its $23 billion acquisition of cancer test maker Exact Sciences, sending its shares down 5% even as the medical device maker narrowly ​beat quarterly results estimates.